Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro
ICIs, specifically Pembrolizumab, Nivolumab, and Ipilimumab, adversely affect human sperm motility <i>in vitro</i>. Further research is required to understand the underlying mechanisms and clinical implications.
Authors
- Ilaria Cosci (ORCID: https://orcid.org/0009-0000-5998-8146)
- Andrea Di Nisio (ORCID: https://orcid.org/0000-0002-7251-9210)
- Alberto Ferlin (ORCID: https://orcid.org/0000-0001-5817-8141)
- Giovanna Crivellaro (ORCID: https://orcid.org/0000-0001-8040-3587)
- Jacopo Pigozzo (ORCID: https://orcid.org/0000-0003-2427-8915)
- Loris Bertazza (ORCID: https://orcid.org/0000-0001-7931-0084)
- Luca De Toni (ORCID: https://orcid.org/0000-0003-4958-5217)
- Marina Coppola (ORCID: https://orcid.org/0009-0002-2026-1067)
- Simone Mocellin (ORCID: https://orcid.org/0000-0002-9433-8445)
- Paolo Del Fiore (ORCID: https://orcid.org/0000-0002-2862-8014)
- Claudia Maria Radu
- Samuela Carraro (ORCID: https://orcid.org/0009-0005-7373-9695)
Institutions
- University of Padua (IT)
- Istituto Oncologico Veneto (IT)
- Pegaso University (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.3389/fphar.2025.1534975
- Citations
- 3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 2.39